Tender detail
Drug discount agreements for the active substance Erythropoietin, ATC B03XA01
Summary
The tender concerns the negotiation of non-exclusive discount contracts for medicines with the active substance Erythropoietin (ATC B03XA01) for the period 01 November 2026 to 31 October 2028, using an open-house model. In the Open House procedure, medicines listed as pediatric medicines according to the BfArM list are excluded.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.